Researchers discovered a promising leukemia drug breakthrough that could help patients overcome treatment resistance, ...

A research team at Oregon Health & Science University has discovered a promising new drug combination that may help people ...

Preclinical AML studies showed palbociclib plus venetoclax produced stronger, more durable anti‑leukemia activity than venetoclax alone and may overcome resistance.

The most-read coverage of the latest updates in acute myeloid leukemia (AML) for 2025 focused on the evolution of targeted therapies, the promise of off-the-shelf chimeric antigen receptor (CAR) ...

Asian patients with newly diagnosed acute myeloid leukemia (AML) may have superior overall survival (OS) outcomes compared with White patients, though further data are needed to corroborate this ...

A recent study shows a regimen of low-dose homoharringtonine, cytarabine, and G-CSF (HAG) is an effective and promising treatment for pediatric patients with AML.

Compared with white patients, Black patients with acute myeloid leukemia (AML) were on average more than five years younger at diagnosis, more than 30% more likely to die of their disease, and more ...

Panelists discuss how venetoclax management requires standardized approaches to duration, bone marrow biopsy timing, growth factor use, and azole antifungal selection, with practices varying ...

SELLAS Life Sciences Virtual R&D Day -- October 29, 2025: Advancing Novel Therapies in Acute Myeloid Leukemia (AML): An Overview of the Ongoing Phase 3 REGAL Trial of Galinpepimut-S (GPS) and SLS009 ...

Black race is an independent prognostic factor for lower survival outcomes in AML, regardless of cytogenetics. Black patients with NPM1 mutations had poorer overall survival compared to White patients ...